

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DigitalX Limited
ABN	59 009 575 035

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	22 March 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Irwin Biotech Nominees Pty Ltd. Peter Irwin Rubinstein is the sole director and shareholder of Irwin Biotech Nominees Pty Ltd.
Date of change	26 – 31 March 2021

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct 617,284 Fully Paid Ordinary Shares</p> <p>Indirect 13,196,296 Fully Paid Ordinary Shares¹ 8,470,000 Fully Paid Ordinary Shares² 3,694,444 Fully Paid Ordinary Shares³ 7,200,000 Fully Paid Ordinary Shares⁴ 1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023¹ 1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023¹ 2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023¹</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd. 2. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust 3. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund 4. Held by ValueAdmin.Com Pty Ltd.</p>
Class	Fully Paid Ordinary Shares
Number acquired	3,000,000 Fully Paid Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$191,993.66 (average of \$0.063 per Share)

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	<p>Direct 617,284 Fully Paid Ordinary Shares</p> <p>Indirect 16,196,296 Fully Paid Ordinary Shares¹ 8,470,000 Fully Paid Ordinary Shares² 3,694,444 Fully Paid Ordinary Shares³ 7,200,000 Fully Paid Ordinary Shares⁴ 1,000,000 Unlisted Options exercisable at \$0.22 each on or before 10 December 2023¹ 1,500,000 Unlisted Options exercisable at \$0.25 each on or before 10 December 2023¹ 2,000,000 Unlisted Options exercisable at \$0.30 each on or before the date 10 December 2023¹</p> <p>1. Held by Irwin Biotech Nominees Pty Ltd. 2. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust 3. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund 4. Held by ValueAdmin.Com Pty Ltd</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market purchase.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.